论文部分内容阅读
目的探讨利妥昔单抗联合化疗治疗弥漫大B细胞性淋巴瘤(DLBCL)的疗效疗效。方法将解放军总院第一附属医院收治的40例DLBCL患者分为观察组和对照组,对照组采用CHPO方案治疗,观察组在对照组的基础上采用利妥昔单抗治疗,比较两组患者的近期临床疗效及不良反应。结果观察组的总有效率为80.0%,显著高于对照组40.0%,P<0.05。其在发热方面显著多于对照组,P<0.05。结论利妥昔单抗联合化疗治疗DLBCL近期疗效较好,全身不良反应较轻。
Objective To investigate the curative effect of rituximab combined with chemotherapy on diffuse large B cell lymphoma (DLBCL). Methods 40 cases of DLBCL patients admitted to the First Affiliated Hospital of Chinese PLA General Hospital were divided into observation group and control group. The control group was treated with CHPO regimen. The observation group was treated with rituximab on the basis of the control group. The recent clinical efficacy and adverse reactions. Results The total effective rate in the observation group was 80.0%, significantly higher than that in the control group (40.0%, P <0.05). It was significantly more in the fever than the control group, P <0.05. Conclusion Rituximab combined with chemotherapy for the treatment of DLBCL recent good effect, systemic adverse reactions less.